Mechanisms of metastasis

Critical Reviews in Oncology/Hematology

Volumn 26, Issue 3, 1997, Pages 163-173

  Ahmad, Athar ^a   Hart, Ian R ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b Department of Veterinary Medicine ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CANCER INVASION; CELL INTERACTION; CELL MIGRATION; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0031431108     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(97)10002-6     Document Type: Article

References (126)

1. Fishcer B, Fischer ER. Interelationship of haematogenous and lymphatic tumor cell dissemination. Surg Gynaecol Obstet 1966;122:791-8.
2. Albelda SM. The role of integrins and other cell adhesion molecules in tumour progression and metastasis. Lab Invest 1993;68:4-17.
3. Liotta LA, Rao CN, Barsky SH. Tumor invasion and the extracellular matrix. Lab Invest 1983;49:636-49.
4. Aresu O, Nicolo G, Allerana G, et al. Invasive activity, spreading on and chemotactic response to laminin are properties of high but not low metastatic mouse osteosarcoma cells. Invasion Metastasis 1991;11:2-13.
5. Yoshinga IG, Vin KJ, Dekker SK, et al. Role of α3β1 and α2β1 integrins in melanoma cell migration. Melanoma Res 1993;3:435-41.
6. Juliano RL. The role of β1 integrins in tumours. Semin Cancer Biol 1993;4:277-83.
7. Duffy MJ. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Methods 1992;10(3):145-55.
8. Tryggvason K, Hoyhtya M, Salo T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987;907:191-207.
9. Murphy G, Reynolds JJ, Hembrey RM. Metalloproteinases and cancer invasion and metastasis. Int J Cancer 1989;44:757-60.
10. Timpl R. Structure and biological activity of basement membane proteins. Eur J Biochem 1989;180:487-502.
11. Farquhar MG. The glomerular basement membrane: a selective macromolecular filter. In: Hay ED, editor. Cell Biology of Extracellular Matrix. New York: Plenum, 1981:3335-3378.
12. Brown PD. Proteinase inhibition: a new approach to cancer therapy. Cancer Top 1993;9:100-1.
13. Ballin M, Gomez DE, Sinha CC, et al. Ras oncogene mediated induction of a 92 kDa metalloproteinase; strong correlation with the malignant phenotype. Biochem Biophys Res Commun 1988;154:832-8.
14. Liotta LA, Trygavasson K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature (London) 1980;284:67-8.
15. Nakajima M, Welch DR, Belloni PN, et al. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res 1987;47:4869-76.
16. Van der Stappen JWJ, Hendriks T, Wobbes T. Correlation between collagenolytic activity and grade of histological differentiation in colorectal tumors. Int J Cancer 1990;45:1071-8.
17. Wirl G, Trick J. Collagenase A marker enzyme in human bladder cancer. Urol Res 1979;7:103-8.
18. Kubochi K, Otani Y. In: Tschesche H, editor. Proteinases in Inflammation and Tumor Invasion. 1980:337-356.
19. D'Errico A, Garbisa S, Liotta LA, et al. Augmentation of type IV collagenase, laminin receptor and Ki67 prolifertion antigen associated with human colon, gastric and breast carcinoma progression. Mod Pathol 1991;4(2):239-46.
20. Garbisa S, Scagliotti G, Masiero L, et al. Correlation of serum metalloproteinase levels with lung cancer metastasis and response to therapy. Cancer Res 1991;52:4548-9.
21. Levy A, Cioce V, Sobel ME, et al. Increased expression of 72 kDa type IV collagenase in human colonic adenocarcinoma. Cancer Res 1991;51:439-44.
22. Monteaggudo C, Merino MJ, San-Juan J, et al. Immunohistochemical distribution of type IV collagenase in normal, benign and malignant breast tissue. Am J Pathol 1990;136:585-92.
23. Basset P, Bellocq JP, Wolf C, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature (London) 1990;348:699-704.
24. Rouyer N, Wolf C, Chenard MP, et al. Stromelysin 3 gene expression in human cancer: an overview. Invasion Metastasis 1994;14:269-75.
25. Engel G, Heselmeyer K, Auer G, et al. Correlation between stromelysin 3 mRNA level and outcome of human breast cancer. Int J Cancer 1993;58(6):830-5.
26. Lippman ME, Dickson RB. Mechanisms of growth control in normal and malignant breast epithelium. Recent Prog Horm Res 1989;45:383-440.
27. Mackay AR, Ballin M, Pelina MD, et al. Effect of phorbol ester and cytokines on matrix metalloproteinase and tissue inhibitor of metalloproteinase expression in tumour and normal cell lines. Invasion Metastasis 1992;12:168-84.
28. Guo HM, Zucker S, Gordon MK, et al. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix netalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem 1997;272:24-7.
29. Ito A, Nakajima S, Sasaguri Y, et al. Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer 1995;71:1039-45.
30. Himelstein BP, Canete-Soler R, Bernhard EJ, et al. Induction of fibroblast 92 kDa/type IV collagenase expression by direct contact with metastatic tumor cells. J Cell Science 1994;107:477-86.
31. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
32. Emmert-Buck MR, Roth MI, Zhuang Z, et al. Increased gelatinase-A (MMP-2) and cathepsin B activity in invasive tumour regions of human colon cancer samples. Am J Pathol 1994;145:1285-90.
33. Duffy MJ. Plasminogen activators and cancer. Blood Coagul Fibrinolysis 1990;1:681-7.
34. Duffy MJ. Do proteases play a role in cancer invasion and metastasis?. Eur J Cancer Clin Oncol 1987;23:583-9.
35. Woesner FJ Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB J 1991;5:2145-54.
36. De Clerck YA, Imren S. Protease inhibitors: role and potential therapeutic use in human cancer. Eur J Cancer 1994;30A(14):2170-80.
37. De Clerck YA, Yean TD, Ratzkin BJ, et al. Inhibition of autoproteolytic activation of interstitial pro-collagenase by recombinant MI/TIMP2. J Biol Chem 1991;266:3893-9.
38. Howard EW, Bullen EC, Banda MJ. Regulation of the auto activation of human 72 kDa pro-gelatinase by TIMP-2. J Biol Chem 1991;266:13064-9.
39. Albini A, Melchiori A, Santi L, et al. Tumor cell invasion by TIMP-2. J Natl Cancer Inst 1991;83:775-9.
40. De Clerck YA, Yean TD, Chand D, et al. Inhibition of tumor invasion of smooth muscle cell layers by recombinant MMP inhibitor. Cancer Res 1991;51:2151-7.
41. Schultz RM, Silberman S, Persky B, et al. Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonisation by murine B 16-F10 melanoma cells. Cancer Res 1988;48:5539-45.
42. Khokha R, Zimmer MJ, Graham SH, et al. Suppression of invasion by inducible expression of TIMP-1 in B 16-F10 melanoma cells. J Natl Cancer Inst 1992;84:1017-22.
43. De Clerck YA, Perez N, Shimoda H, et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-8.
44. Blei F, Wilson EL, Mignatti P, et al. Mechanism of action of angiostatic steroids; suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis. J Cell Physiol 1993;155:568-78.
45. Johnson MD, Kim HR, Chester L, et al. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994;160:194-202.
46. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995;6:967-74.
47. Talbot DC, Brown PD. Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Eur J Cancer (Special Issue: Basic and Clinical research on Angiogenesis) 1996;14:2528-33.
48. Gore M, A'Hern R, Stankiewicz M, et al. Tumour marker levels during marimastat therapy. Lancet 1996;348:263-4.
49. Testa JE, Quigley JP. The role of uPA in aggressive tumor cell behaviour. Cancer Metastasis Rev 1990;9:353-67.
50. Miller LB. Structure and function of the urokinase receptor. Coagul Fibrinolysis 1993;4:292-303.
51. Ellis V, Pyke C, Eriksen J, et al. The urokinase receptor: involvement in cell surface proteolysis and cancer invasion. Ann New York Acad Sci 1992;667:13-31.
52. Wei Y, Waltz DA, Rao N, et al. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994;269(51):32380-8.
53. Skriver L, Larsson L, Kielberg V, et al. Immunocytochemical localisation of uPA in Lewis lung carcinoma. J Cell Biol 1984;99:753-8.
54. Grondahl-Hansen J, Ralfkizr E, Kirkeby LT, et al. Localisation of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991;138:111-7.
55. Pyke C, Kristensen P, Ralfkizr E, et al. uPA is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colonic adenocarcinomas. Am J Pathol. 1991;138:1059-67.
56. Duffy MJ, O'Grady P, Devney D, et al. uPA, a marker for aggressive breast cancers. Preliminary report. Cancer 1988;62:531-3.
57. Grondahl-Hansen J, Christensen IJ, Rosenquist C, et al. High levels of uPA and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993;53:2513-21.
58. Duffy MJ, Reilly D, O'Sullivan C, et al. uPA - a new and independent prognostic marker in breast cancer. Cancer Res 1990;50:6827-9.
59. Sloane BF. Cathepsin B and cystatins: evidence for a role in cancer progression. Semin Cancer Biol 1990;1:137-52.
60. Sloane BF, Rozhin J, Johnson K, et al. Cathepsin B: assocation with plasma membrane in metastatic tumours. Proc Natl Acad Sci USA 1986;83:2483-7.
61. Hahnel R, Harvey J, Robbins P, et al. Cathepsin D in human breast cancer: correlation with vascular invasion and other clinical and histopathological characteristics. Anticancer Res 1993;13:2131-5.
62. Johnson MD, Torri JA, Lippman ME, et al. Cathepsin D in invasiveness of human breast cancer cells. Cancer Res 1993;53:873-7.
63. Garcia M, Dercocq D, Pujol P, et al. Overexpression of transfected Cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene 1990;5:1809-14.
64. Franks LM. In: Franks LM, Teich NM, editors. What is Cancer? Introduction to the Cellular and Molecular Biology of Cancer. London: Oxford University Press, 1991:1-30.
65. Van Roy F, Mareel M. Tumour cell invasion: effects of cell adhesion and motility. Trends Cell Biol 1992;2:163-9.
66. Weinstein RS, Merk FB, Alroy J. The structure and function of intercellular junctions in cancer. Adv Cancer Res 1976;23:23-89.
67. Jounanneau J, Tucker GC, Boyer B, et al. Epithelial cell plasticity in neoplasia. Cancer Cells 1991;12:525-9.
68. Hynes RO, Lander AD. Contact and adhesive specifications in the associations, migrations and targeting of cells and axons. Cell 1992;68:303-22.
69. Coman DR. Decreased mutual adhesiveness, a property of cells from squamous carcinomas. Cancer Res 1944;20:1202-4.
70. Ozawa M, Baribault H, Kemler R. The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 1989;8:1711-7.
71. Takeichi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science (Washington, DC) 1991;251:1451-5.
72. 2+ dependent adhesion molecules. Trends Biochem Sci 1988;13:75-6.
73. Grunwald G. The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. Curr Opin Cell Biol 1993;5:797-805.
74. Vestweber D, Kemler R. Identification of a putative cell adhesion domain of uvomorulin. EMBO J 1985;4:3393-8.
75. Behrens J, Birchmeir W, Goodman SL, et al. Dissociation of Madin-Darby Canine Kidney epithelial cells by the monoclonal antibody anti-arc-1. J Cell Biol 1985;101:1307-15.
76. Behrens J, Mareel M, Van Roy F, et al. Dissecting tumour cell invasion: epithelial cells acquire invasive properties after loss of uvomorulin-mediated cell adhesion. J Cell Biol 1989;108:2435-7.
77. Behrens J. The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res Treat 1993;24:175-84.
78. Navarro P, Gomex M, Pizarro A, et al. A role for the E-cadherin cell-cell adhesion molecule during tumor progression of mouse epidermal carcinogenesis. J Cell Biol 1991;115:517-33.
79. Frixen UH, Behrens J, Sachs M, et al. E-cadherin mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 1991;113:173-85.
80. Chen W, Obrink B. Cell-cell contacts mediated by E-cadherin restrict invasive behaviour of L-cells. J Cell Biol 1991;114:319-27.
81. Dorudi S, Sheffield JP, Poulsom R, et al. E-cadherin expression in colorectal cancer. Am J Pathol 1993;142:981-6.
82. Shiozaku H, Tahara H, Oka H, et al. Expression of E-cadherin adhesion molecules in human cancers. Am J Pathol 1991;139:17-23.
83. Tohma Y, Yamashima T, Yamashitata J, et al. Immunohistochemical localisation of cell adhesion molecule E-cadherin in human arachnoid villi and meningiomas. Cancer Res 1992;52:1981-7.
84. Umbas R, Schalken J, Aalders TW. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52:5104-9.
85. Shimoyama Y, Hirohasi S, Hirano S, et al. Cadherin cell adhesion molecules in human epithelial tissues and carcinomas. Cancer Res 1991;49:2128-33.
86. Eidelman S, Damsky CH, Wheelock MJ, et al. Expression of the cell-cell adhesion glycoprotein cell-CAM 120/80 in normal human tissues and tumours. Am J Pathol 1989;135:101-10.
87. Berx G, Cleton-Jansen AM, Nollet F, et al. E-Cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 1995;14(24):6107-15.
88. Pierceall WE, Woodard AS, Morrow JS, et al. Frequent alterations in E-cadherin and alpha-and beta-catenin expression in human breast cancer cell lines. Oncogene 1995;11(7):1319-26.
89. Humphries MJ. The molecular basis and specificity of integrin-ligand interactions. J Cell Sci 1990;97:585-92.
90. Albelda SM, Buck CA. Integrins and other cell adhesion molecules. FASEB J 1990;4:2868-80.
91. Hynes RO. Integrins: versatility, modulation, and signalling in cell adhesion. Cell 1992;69:11-25.
92. Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-34.
93. Humphries MJ, Olden K, Yamada K. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986;233:467-70.
94. Ruiz P, Dunon D, Sonnenberg A, et al. Suppression of mouse melanoma metastases by EA-1, a monclonal antibody specific for α6 integrins. Cell Adhes Commun 1993;1:67-81.
95. Albelda SM, Mette SA, Elder DE, et al. Integrin distribution in malignant melanoma: assocation of the β3 subunit with tumor progression. Cancer Res 1990;50:6757-64.
96. Albelda SM. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993;68:4-17.
97. Schadendorf D, Gawlick C, Haney U, et al. Tumor progression and metastatic behaviour in vivo correlates with integrin expression on melanocytic tumors. J Pathol 1993;170:429-34.
98. Moretti S, Martini L, Berti E. Adhesion molecule profile and malignancy of melanocytic lesions. Melanoma Res 1993;3:235-9.
99. Damjanovich L, Albelda SM, Mette SA, et al. The distribution of integrin cell adhesion receptors in normal and malignant lung tissue. J Immunol 1992;148:1985-92.
100. Hall PA, Coates P, Lemoine NR, et al. Characterisation of integrin chains in normal and neoplastic human pancreas. J Pathol 1991;163:307-13.
101. Zutter MM, Krigman HR, Santoro SA. Altered integrin expression in adenocarcinoma of the breast: Analysis by in-situ hybridisation. Am J Pathol 1993;142:1439-48.
102. Brooks PC, Stromblad S, Sanders LC, et al. Localisation of MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell 1996;79:1157-64.
103. Goridis C, Brunet JF. NCAM: structural diversity, function and regulation of expression. Semin Cell Biol 1992;3:189-97.
104. Holzmann B, Brocker EB, Lehman J, et al. Tumour progression in human malignant melanoma: five stages defined by their antigenic phenotypes. Int J Cancer 1987;39:466-71.
105. Holzmann B, Lehman J, Ziegler-Herdbrook L. Glycoprotein p3.58 associated with tumor progression in malignant melanoma, is a novel leucocyte activation antigen. Int J Cancer 1988;41:542-7.
106. Johnson JP. Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Cancer Metastasis Rev 1991;10:11.
107. Altomonte M, Gloghine A, Bertola G, et al. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 on human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 1993;1:3343-8.
108. Pujol JL, Simony J, Demoly P, et al. Neural cell adhesion molecule and prognosis of surgically resected lung cancer. Am Rev Respir Dis 1993;148:1071-5.
109. Michelides R, Kwa B, Springall D, et al. NCAM and lung cancer. Int J Cancer 1994;8, Suppl:34-7.
110. Rosen EM, Knesel J, Goldberg ID. Scatter factor and its relationship to hepatocyte growth factor and met. Cell Growth Differ 1991;2:603-7.
111. Kohn EC, Liotta LA. Molecular insights into cancer invasion: stratagies for prevention and intervention. Cancer Res 1995;55:1856-62.
112. Foulds L. The experimental study of tumor progression. Cancer Res 1964;14:327-39.
113. Jendraschak E, Sage EH. Regulation of angiogenesis by SPARC and angiostatin: implications for tumour cell biology. Semin Cancer Biol 1996;7:139-46.
114. Mignatti P, Tsuboi R, Robbins E, et al. In vitro angiogenesis on the human amniotic membrane: Requirement for bFGF-induced proteinases. J Cell Biol 1989;108:671-82.
115. Bussolino F, Albini A, Camussi G, et al. Role of soluble mediators in angiogenesis. Eur J Cancer (Special Issue: Basic and Clinical Research on Angiogenesis) 1996;14:2401-12.
116. Ferrara N. Vascular endothelial growth factor. Eur J Cancer (Special Issue: Basic and Clinical Research on Angiogenesis) 1996;14:2413-22.
117. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1995;1:27-31.
118. Prehn RT. The inhibition of tumor growth by tumor mass. Cancer Res 1991;51:2-4.
119. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
120. Weidner N, Semple J, Welch W, et al. Tumor angiogenesis correlates with metastasis in invasive breast carcinoma. New Engl J Med 1991;324:1-8.
121. Macchiarini P, Fontanini G, Hardin MJ, et al. Relation of neovascularisation to metastasis of non-small cell lung cancer. Lancet 1992;340:145-6.
122. Murphy AN, Unsworth EJ, Stetler-Stevensen WG. TIMP-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993;157:351-8.
123. Tarabdetti G, Garosabo A, Belotti D, et al. Inhibition of angiogenesis and murine haemangioma growth by barimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1995;87:293-8.
124. Ingber D, Fujota T, Kishimoto S, et al. Synthetic analogs of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990;348:555-7.
125. Marione TE, Gray GS, Petro J, et al. Inhibition of angiogenesis by recombinant human platelet factor-4 and related pep tides. Science 1990;247:77-9.
126. Brooks PC. Role of integrins in angiogenesis. Eur J Cancer (Special Issue: Basic and Clinical Research on Angiogenesis) 1996;14:2423-9.